Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2008

Open Access 01-12-2008 | Research article

Triphala inhibits both in vitro and in vivo xenograft growth of pancreatic tumor cells by inducing apoptosis

Authors: Yan Shi, Ravi P Sahu, Sanjay K Srivastava

Published in: BMC Cancer | Issue 1/2008

Login to get access

Abstract

Background

Triphala is commonly used in Ayurvedic medicine to treat variety of diseases; however its mechanism of action remains unexplored. This study elucidates the molecular mechanism of Triphala against human pancreatic cancer in the cellular and in vivo model.

Methods

Growth-inhibitory effects of Triphala were evaluated in Capan-2, BxPC-3 and HPDE-6 cells by Sulphoradamine-B assay. Apoptosis was determined by cell death assay and western blotting. Triphala was administered orally to nude mice implanted with Capan-2 xenograft. Tumors were analyzed by immunohistochemistry and western blotting.

Results

Exposure of Capan-2 cells to the aqueous extract of Triphala for 24 h resulted in the significant decrease in the survival of cells in a dose-dependent manner with an IC50 of about 50 μg/ml. Triphala-mediated reduced cell survival correlated with induction of apoptosis, which was associated with reactive oxygen species (ROS) generation. Triphala-induced apoptosis was linked with phosphorylation of p53 at Ser-15 and ERK at Thr-202/Tyr-204 in Capan-2 cells. Above mentioned effects were significantly blocked when the cells were pretreated with an antioxidant N-acetylcysteine (NAC), suggesting the involvement of ROS generation. Pretreatment of cells with pifithrin-α or U0126, specific inhibitors of p53 or MEK-1/2, significantly attenuated Triphala-induced apoptosis. Moreover, NAC or U0126 pretreatment significantly attenuated Triphala-induced p53 transcriptional activity. Similarly, Triphala induced apoptosis in another pancreatic cancer cell line BxPC-3 by activating ERK. On the other hand, Triphala failed to induce apoptosis or activate ERK or p53 in normal human pancreatic ductal epithelial (HPDE-6) cells. Further, oral administration of 50 mg/kg or 100 mg/kg Triphala in PBS, 5 days/week significantly suppressed the growth of Capan-2 pancreatic tumor-xenograft. Reduced tumor-growth in Triphala fed mice was due to increased apoptosis in the tumors cells, which was associated with increased activation of p53 and ERK.

Conclusion

Our preclinical studies demonstrate that Triphala is effective in inhibiting the growth of human pancreatic cancer cells in both cellular and in vivo model. Our data also suggests that the growth inhibitory effects of Triphala is mediated by the activation of ERK and p53 and shows potential for the treatment and/or prevention of human pancreatic cancer.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics, 2005. CA Cancer J Clin. 2005, 55 (1): 10-30. Erratum in: CA Cancer J Clin. 2005; 55(4):259CrossRefPubMed
2.
Niederhuber JE, Brennan MF, Mench HR: The National Cancer Data Base Report on Pancreatic Cancer. Cancer. 1995, 76: 1671-7. 10.1002/1097-0142(19951101)76:9<1671::AID-CNCR2820760926>3.0.CO;2-R.CrossRefPubMed
3.
4.
Sarkar FH, Banerjee S, Li YW: Pancreatic cancer: Pathogenesis, prevention and treatment. Toxicol Appl Pharmacol. 2007, 224: 326-36. 10.1016/j.taap.2006.11.007.CrossRefPubMed
5.
Stefañska B, Arciemiuk M, Bontemps-Gracz MM, Dzieduszycka M, Kupiec A, Martelli S, Borowski E: Synthesis and biological evaluation of 2,7-Dihydro-3H-dibenzo[de,h] cinnoline-3,7-dione derivatives, a novel group of anticancer agents active on a multidrug resistant cell line. Bioorg Med Chem. 2003, 11: 561-72. 10.1016/S0968-0896(02)00425-X.CrossRefPubMed
6.
Sahani DV, Shah ZK, Catalano OA, Boland GW, Brugge WR: Radiology of pancreatic adenocarcinoma: current status of imaging. J Gastroenterol Hepatol. 2008, 23: 23-33. 10.1111/j.1440-1746.2007.04868.x.CrossRefPubMed
7.
Cherng JM, Shieh DE, Chiang W, Chang MY, Chiang C: Chemopreventive effects of minor dietary constituents in common foods on human cancer cells. Biosci Biotechnol Biochem. 2007, 71: 1500-4. 10.1271/bbb.70008.CrossRefPubMed
8.
Feng R, Ni HM, Wang SY, Tourkova IL, Shurin MR, Harada H, Yin XM: Cyanidin-3-rutinoside, a natural polyphenol antioxidant, selectively kills leukemic cells by induction of oxidative stress. J Biol Chem. 2007, 282: 13468-76. 10.1074/jbc.M610616200.CrossRefPubMed
9.
Aggarwal BB, Shishodia S: Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol. 2006, 71: 1397-1421. 10.1016/j.bcp.2006.02.009.CrossRefPubMed
10.
Jagetia GC, Baliga MS, Malagi KJ, Sethukumar Kamath M: The evaluation of the radioprotective effect of Triphala (an ayurvedic rejuvenating drug) in the mice exposed to gamma-radiation. Phytomedicine. 2002, 9: 99-108. 10.1078/0944-7113-00095.CrossRefPubMed
11.
Kaur S, Arora S, Kaur K, Kumar S: The in vitro antimutagenic activity of Triphala- an Indian herbal drug. Food Chem Toxicol. 2002, 40: 527-34. 10.1016/S0278-6915(01)00101-6.CrossRefPubMed
12.
Singh DP, Govindarajan R, Rawat AK: High-performance liquid chromatography as a tool for the chemical standardization of Triphala-an Ayurvedic formulation. Phytochem Anal. 2008, 19: 164-8. 10.1002/pca.1032.CrossRefPubMed
13.
Deep G, Dhiman M, Rao AR, Kale RK: Chemopreventive potential of Triphala (a composite Indian drug) on benzo(a)pyrene induced forestomach tumorigenesis in murine tumor model system. J Exp Clin Cancer Res. 2005, 24: 555-63.PubMed
14.
Sandhya T, Mishra KP: Cytotoxic response of breast cancer cell lines, MCF-7 and T 47D to triphala and its modification by antioxidants. Cancer Lett. 2006, 238: 304-13. 10.1016/j.canlet.2005.07.013.CrossRefPubMed
15.
Sandhya T, Lathika KM, Pandey BN, Mishra KP: Potential of traditional ayurvedic formulation, Triphala as a novel anticancer drug. Cancer Lett. 2006, 231: 206-214. 10.1016/j.canlet.2005.01.035.CrossRefPubMed
16.
Sandhya T, Lathika KM, Pandey BN, Bhilwade HN, Chaubey RC, Priyadarsini KI, Mishra KP: Protection against radiation oxidative damage in mice by Triphala. Mutation Res. 2006, 609: 17-25.CrossRefPubMed
17.
Furukawa T, Duguid WP, Rosenberg L, Viallet J, Galloway DA, Tsao MS: Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. Am J Pathol. 1996, 148: 1763-70.PubMedPubMedCentral
18.
Ouyang H, Mou Lj, Luk C, Liu N, Karaskova J, Squire J, Tsao MS: Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am J Pathol. 2000, 157: 1623-31.CrossRefPubMedPubMedCentral
19.
Srivastava SK, Singh SV: Cell cycle arrest, apoptosis induction and inhibition of nuclear factor kappa B activation in anti-proliferative activity of benzyl isothiocyanate against human pancreatic cancer cells. Carcinogenesis. 2004, 25: 1701-9. 10.1093/carcin/bgh179.CrossRefPubMed
20.
Zhang R, Loganathan S, Humphreys I, Srivastava SK: Benzyl isothiocyanate-induced DNA damage causes G2/M cell cycle arrest and apoptosis in human pancreatic cancer cells. J Nutr. 2006, 136: 2728-34.PubMed
21.
Srivastava SK, Xiao D, Lew KL, Hershberger P, Kokkinakis DM, Johnson CS, Trump DL, Singh SV: Allyl isothiocyanate, a natural constituent of cruciferous vegetables, inhibits growth of PC-3 human prostate cancer xenografts in vivo. Carcinogenesis. 2003, 24: 1665-70. 10.1093/carcin/bgg123.CrossRefPubMed
22.
Liebermann DA, Hoffman B, Vesely D: p53 induced growth arrest versus apoptosis and its modulation by survival cytokines. Cell Cycle. 2007, 6: 166-70.CrossRefPubMed
23.
Lin T, Mak NK, Yang MS: MAPK regulate p53-dependent cell death induced by benzo[a]pyrene: involvement of p53 phosphorylation and acetylation. Toxocology. 2008, 247: 145-153. 10.1016/j.tox.2008.02.017.CrossRef
24.
Persons DL, Yazlovitskaya EM, Pelling JC: Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. J Biol Chem. 2000, 275: 35778-85. 10.1074/jbc.M004267200.CrossRefPubMed
25.
Ito K, Nakazato T, Yamato K, Miyakawa Y, Yamada T, Hozumi N, Segawa K, Ikeda Y, Kizaki M: Induction of apoptosis in leukemic cells by homovanillic acid derivative, capsaicin, through oxidative stress: implication of phosphorylation of p53 at ser-15 residue by reactive species. Cancer Res. 2004, 64: 1071-8. 10.1158/0008-5472.CAN-03-1670.CrossRefPubMed
26.
Singh SV, Srivastava SK, Choi S, Lew KL, Antosiewicz J, Xiao D, Zeng Y, Watkins SC, Johnson CS, Trump DL, Lee YJ, Xiao H, Herman-Antosiewicz : Sulphoraphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species. J Biol Chem. 2005, 280: 19911-24. 10.1074/jbc.M412443200.CrossRefPubMed
27.
Dong LF, Swettenham E, Eliasson J, Wang XF, Gold M, Medunic Y, Stantic M, Low P, Prochazka L, Witting PK, Turanek J, Akporiaye ET, Ralph SJ, Neuzil J: Vitamin E analogues inhibit angiogenesis by selective induction of apoptosis in proliferating endothelial cells: the role of oxidative stress. Cancer Res. 2007, 67: 11906-13. 10.1158/0008-5472.CAN-07-3034.CrossRefPubMed
28.
Mclean L, Soto U, Agama K, Agama K, Francis J, Jimenez R, Pommier Y, Sowers L, Brantley E: Aminoflavone induces oxidative DNA damage and reactive oxidative species-mediated apoptosis in breast cancer cells. Int J Cancer. 2008, 22: 1665-74. 10.1002/ijc.23244.
29.
Lau AT, Wang Y, Chiu JF: Reactive oxygen species: Current knowledge and applications in cancer research and therapeutic. J Cell Biochem. 2008, 104: 657-67. 10.1002/jcb.21655.CrossRefPubMed
30.
Ganguly A, Das B, Roy A, Sen N, Dasgupta SB, Mukhopadhayay S, Majumder HK: Betulinic acid, a catalytic inhibitor of topoisomerase I, inhibits reactive oxygen species-mediated apoptotic topoisomerase I-DNA cleavable complex formation in prostate cancer cells but does not affect the process of cell death. Cancer Res. 2007, 67: 11848-58. 10.1158/0008-5472.CAN-07-1615.CrossRefPubMed
31.
Martirosyan A, Leonard S, Shi X, Griffith B, Gannett P, Strobl J: Action of a histone deacetylase inhibitor NSC3852 (5-nitroso-8-quinolinol) link reactive oxygen species to cell differentiation and apoptosis in MCF-7 human mammary tumor cells. Pharmacol Exp Ther. 2006, 317: 546-52. 10.1124/jpet.105.096891.CrossRef
32.
Saito S, Goodarzi AA, Higashimoto Y, Noda Y, Lees-Miller SP, Appella E, Anderson CW: ATM mediates phosphorylation at multiple p53 sites, including Ser (46), in response to ionizing radiation. J Biol Chem. 2002, 277: 12491-4. 10.1074/jbc.C200093200.CrossRefPubMed
33.
Pabla N, Huang S, Mi QS, Damiel R, Dong Z: ATR-chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J Biol Chem. 2008, 283: 6572-83. 10.1074/jbc.M707568200.CrossRefPubMed
34.
Gottifredi V, Shieh S, Taya Y, Prives C: p53 accumulates but is functionally impaired when DNA synthesis is blocked. Proc Natl Acad Sci USA. 2001, 98: 1036-41. 10.1073/pnas.021282898.CrossRefPubMedPubMedCentral
35.
Wu SJ, Ng LT: MAPK inhibitors and pifithrin-alpha block cinnamaldehyde-induced apoptosis in human PLC/PRF/5 cells. Food Chem Toxicol. 2007, 45: 2446-53. 10.1016/j.fct.2007.05.032.CrossRefPubMed
36.
Ma Y, Yu WD, Kong RX, Trump DL, Johnson CS: Role of nongenomic activation of phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase 1/2 pathway in 1,25D3-mediated apoptosis in squamous cell carcinoma cells. Cancer Res. 2006, 66: 8131-8. 10.1158/0008-5472.CAN-06-1333.CrossRefPubMed
37.
Singh S, Upadhyav AK, Ajay AK, Bhat MK: p53 regulates ERK activation in carboplatin induced apoptosis in cervical carcinoma: a novel target of p53 in apoptosis. FEBS Lett. 2007, 581: 289-95. 10.1016/j.febslet.2006.12.035.CrossRefPubMed
38.
Jeon ES, Lee MJ, Sung SM, Kim JH: Sphingosylphosphorylcholine induces apoptosis of endothelial cells through reactive oxygen species-mediated activation of ERK. J Cell Biochem. 2007, 100: 1536-47. 10.1002/jcb.21141.CrossRefPubMed
39.
Xu C, Shen G, Yuan X, Kim JH, Gopalkrishnan A, Keum YS, Nair S, Kong AN: ERK and JNK signaling pathways are involved in the regulation of activator protein 1 and cell death elicited by three isothiocyanates in human prostate cancer PC-3 cells. Carcinogenesis. 2006, 27: 437-45. 10.1093/carcin/bgi251.CrossRefPubMed
40.
Choi YJ, Lim SY, Woo JH, Kim YH, Kwon YK, Suh SI, Lee SH, Choi WY, Kim JG, Lee IS, Park JW, Kwon TK: Sodium orthovanadate potentiates EGCG-induced apoptosis that is dependent on the ERK pathway. Biochem Biophys Res Commun. 2003, 305: 176-85. 10.1016/S0006-291X(03)00719-8.CrossRefPubMed
41.
Yu W, Liao QY, Hantash FM, Sanders BG, Kline K: Activation of extracellular signal-regulated kinase and c-Jun-NH(2)-terminal kinase but not p38 mitogen-activated protein kinases is required for RRR-alpha-tocopheryl succinate-induced apoptosis of human breast cancer cells. Cancer Res. 2001, 61: 6569-76.PubMed
42.
Zhou Q, Meng D, Yan B, Jiang BH, Fang J: Transactivation of epidermal growth factor receptor by insulin-like growth factor 1 requires basal hydrogen peroxide. FEBS Lett. 2006, 580: 5161-6. 10.1016/j.febslet.2006.08.068.CrossRefPubMed
43.
Lee JS, Kim SY, Kwon CH, Kim YK: EGFR-dependent ERK activation triggers hydrogen peroxide-induced apoptosis in OK renal epithelial cells. Arch Toxicol. 2006, 80: 337-46. 10.1007/s00204-005-0052-2.CrossRefPubMed
44.
Midwinter RG, Peskin AV, Vissers MC, Winterbourn CC: Extracellular oxidation by taurine chloramine activates ERK via the epidermal growth factor receptor. J Biol Chem. 2004, 279: 32205-11. 10.1074/jbc.M402070200.CrossRefPubMed
45.
Arany I, Megyesi JK, Kaneto H, Price PM, Safirstein RL: Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. Am J Physiol Renal Physiol. 2004, 287: F543-9. 10.1152/ajprenal.00112.2004.CrossRefPubMed
46.
Höcker M, Rosenberg I, Xavier R, Henihan RJ, Wieham RJ, Wiedernmann B, Rosewicz S, Podolsky DK, Wanf TC: Oxidative stress activates the human histidine decarboxylase promoter in AGS gastric cancer cells. J Biol Chem. 1998, 273: 23046-54. 10.1074/jbc.273.36.23046.CrossRefPubMed
47.
Bodo J, Jakubikova J, Chalupa I, Bartosova Z, horakova K, Floch L, Sedlak J: Apoptotic effect of ethyl-4-isothiocyanatobutanoate is associated with DNA damage, proteasomal activity and induction of p53 and p21cip1/waf1. Apoptosis. 2006, 11: 1299-310. 10.1007/s10495-006-8760-5.CrossRefPubMed
48.
Lee JH, Kim KT: Regulation of cyclin-dependent kinase 5 and p53 by ERK1/2 pathway in the DNA damage-induced neuronal death. J Cell Physiol. 2007, 210: 784-97. 10.1002/jcp.20899.CrossRefPubMed
49.
Tang D, Wu D, Hirao A, Lahti JM, Liu L, Mazza B, Kidd VJ, Mak TW, Ingram AJ: ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J Biol Chem. 2002, 277: 12710-7. 10.1074/jbc.M111598200.CrossRefPubMed
50.
Baxer NN, Whitson BA, Tuttle TM: Trends in the treatment and outcome of pancreatic cancer in the United States. Ann Surg Oncol. 2007, 14: 1320-6. 10.1245/s10434-006-9249-8.CrossRef
51.
Rastogi T, Devesa S, Mangtani P, Mathew A, Cooper N, Kao R, Sinha R: Cancer incidence rates among south Asians in four geographic regions: India, Singapore, UK and US. Int J Epidemiol. 2007, 37: 147-60. 10.1093/ije/dym219.CrossRefPubMed
52.
Dhir V, Mohandas KM: Epidemiology of digestive tract cancers in India IV. Gall bladder and pancreas. Indian J Gastroenterol. 1999, 18: 24-8.PubMed
53.
Dorai T, Aggarwal BB: Role of chemopreventive agents in cancer therapy. Cancer Lett. 2004, 215: 129-40. 10.1016/j.canlet.2004.07.013.CrossRefPubMed
54.
Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, Khosh DB, Drisko J, Levine M: Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. PNAS. 2008, 105: 11105-11109. 10.1073/pnas.0804226105.CrossRefPubMedPubMedCentral
Metadata
Title
Triphala inhibits both in vitro and in vivo xenograft growth of pancreatic tumor cells by inducing apoptosis
Authors
Yan Shi
Ravi P Sahu
Sanjay K Srivastava
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-8-294

Other articles of this Issue 1/2008

BMC Cancer 1/2008 Go to the issue

Research article

Sex-specific incidence and temporal trends in solid tumours in young people from Northern England, 1968–2005

Research article

Prodrug converting enzyme gene delivery by L. monocytogenes

Research article

The function of BCL9 in Wnt/β-catenin signaling and colorectal cancer cells

Research article

The clinicopathological and prognostic impact of 14-3-3 sigma expression on vulvar squamous cell carcinomas

Research article

Native human autoantibodies targeting GIPC1 identify differential expression in malignant tumors of the breast and ovary

Research article

Heat shock protein90 in lobular neoplasia of the breast
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits